Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Average Price Target from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.40.

RXRX has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $3.64 on Monday. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.89 billion, a PE ratio of -2.46 and a beta of 0.97. The business has a 50 day moving average of $4.13 and a 200-day moving average of $4.65. Recursion Pharmaceuticals has a 12-month low of $2.98 and a 12-month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. The business’s revenue was up 671.7% on a year-over-year basis. As a group, sell-side analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Activity

In other news, Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00. Following the completion of the transaction, the director owned 6,429,863 shares in the company, valued at approximately $27,005,424.60. This represents a 3.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Najat Khan sold 124,403 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the sale, the insider owned 611,135 shares in the company, valued at $2,695,105.35. This represents a 16.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 599,212 shares of company stock valued at $2,562,550 in the last 90 days. Insiders own 8.43% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its holdings in Recursion Pharmaceuticals by 25.8% during the 4th quarter. Invesco Ltd. now owns 526,144 shares of the company’s stock valued at $2,152,000 after acquiring an additional 107,979 shares during the period. Corient Private Wealth LLC bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $70,000. Mercer Global Advisors Inc. ADV grew its position in shares of Recursion Pharmaceuticals by 55.5% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 25,020 shares of the company’s stock valued at $100,000 after purchasing an additional 8,935 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 149.5% during the 4th quarter. NewEdge Advisors LLC now owns 33,757 shares of the company’s stock valued at $138,000 after purchasing an additional 20,226 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Recursion Pharmaceuticals by 104.0% during the 4th quarter. XTX Topco Ltd now owns 47,908 shares of the company’s stock valued at $196,000 after purchasing an additional 24,421 shares during the period. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.